Restoring Mobility: Roles of Percutaneous Consolidation for Pelvic Ring Bone Lesions
Restoring Mobility: Roles of Percutaneous Consolidation for Pelvic Ring Bone Lesions -a Multicenter Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Nice, France
- CHU NICE
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion :
- Individuals with cancer who underwent percutaneous screw fixation or cementoplasty either for prophylactic consolidation or treatment of pathologic fractures in pelvic ring tumors.
Exclusion criteria :
- minors
- incompetent adults
- refused to participate in the study
- pregnant women
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative weight-bearing ambulation
Time Frame: During hospitalization, mainly less than 3 days
|
the ability of the patient to walk and bear weight after the procedure and its associated timeframe.
|
During hospitalization, mainly less than 3 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse event
Time Frame: During hospitalization, and follow-up
|
adverse event during procedure or hospitalization
|
During hospitalization, and follow-up
|
|
Duration of hospitalization
Time Frame: Mainly less than 3 days
|
The duration of hospitalization will be measured between the day and time of arrival at the hospital and the day and time of discharge from the hospital
|
Mainly less than 3 days
|
|
Long-term effectiveness in preventing pathological fractures of the pelvic ring
Time Frame: 3 months after the procedure, and during follow-up, up to 5 years
|
Absence of pelvic ring fracture during follow-up
|
3 months after the procedure, and during follow-up, up to 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 23Imagerie02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.